PORT 77
Alternative Names: PORT-77Latest Information Update: 03 May 2024
At a glance
- Originator Portal Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 04 Apr 2024 Preclinical trials in Unspecified in USA (unspecified route)
- 04 Apr 2024 Portal Therapeutics plans phase I trial in healthy adult volunteers in US (PO) (NCT06346509)